Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Inflammation

Canakinumab for the cryopyrin-associated periodic syndromes

Nature Reviews Rheumatology volume 5, pages 529–530 (2009)Cite this article

Biologic therapies that target interleukin (IL)-1 are known to dramatically improve symptoms of a group of rare, heritable chronic inflammatory diseases. The results of a phase III trial confirm the place of canakinumab in the treatment arsenal for these disorders.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mathews, R. J., Sprakes, M. & McDermott, M. F. Nod-like receptors and inflammation. Arthritis Res. Ther. 10, 228 (2008).

  2. Agostini, L. et al. NALP3 forms an Il-1β-processing inflammasome with increased activity in Muckle–Wells autoinflammatory disorder. Immunity 30, 319–325 (2004).

    Article  Google Scholar 

  3. Mansky-Goldbach, R. et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N. Engl. J. Med. 355, 581–592 (2006).

    Article  Google Scholar 

  4. Lachmann, H. J. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416–2425 (2009).

    Article  CAS  Google Scholar 

  5. Lachmann, H. J. et al. In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes. J. Exp. Med. 206, 1029–1036 (2009).

    Article  CAS  Google Scholar 

  6. Hoffman, H. M. et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58, 2443–2452 (2008).

    Article  CAS  Google Scholar 

  7. Ruperto, N. et al. A phase II trial with canakinumab (ACZ885), A new IL-1β blocking monoclonal antibody to evaluate the safety and preliminary efficacy in children with systemic juvenile idiopathic arthritis [abstract OP-0298]. Arthritis Rheum. 68 (Suppl. 3), 170–171 (2009).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NIHR-Leeds Musculoskeletal Biomedical Research Unit (NIHR-LMBRU), Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, UK

    Sinisa Savic & Michael F. McDermott

Authors
  1. Sinisa Savic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael F. McDermott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael F. McDermott.

Ethics declarations

Competing interests

S. Savic and M. F. McDermott have acted as consultants for Novartis Pharma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Savic, S., McDermott, M. Canakinumab for the cryopyrin-associated periodic syndromes. Nat Rev Rheumatol 5, 529–530 (2009). https://doi.org/10.1038/nrrheum.2009.195

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2009.195

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing